ArticleInternational journal of hematology2016
Clinical features and treatment outcome of Epstein-Barr virus-positive nodal T-cell lymphoma.
Article in International journal of hematology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 22 citations in OpenAlex.
- Successful Allogeneic Hematopoietic Stem Cell Transplantation for Nodal Epstein-Barr Virus-positive T/NK-cell Lymphoma.Internal medicine (Tokyo, Japan) · 2025Article
- Modified SMILE (mSMILE) is active in the treatment of pediatric Epstein-Barr virus-associated natural killer/T-cell lymphoma: a single center experience, case series.Translational pediatrics · 2024Article
- MicroRNAs targeted mTOR as therapeutic agents to improve radiotherapy outcome.Cancer cell international · 2024Review
- What is new in the 5th edition of the World Health Organization classification of mature B and T/NK cell tumors and stromal neoplasms?Journal of hematopathology · 2024Review
- Metachronous spinal cord involvement B cell and subcutaneous tissue involvement NK/T cell lymphoid proliferations and lymphomas arising in post-transplantation mimicking general NK/T cell lymphoma: a case report and review of the literature.Frontiers in immunology · 2024Review
- A Comparison of the Fifth World Health Organization and the International Consensus Classifications of Mature T-Cell Lymphomas.International journal of molecular sciences · 2023Review
- Cytotoxic peripheral T-cell lymphomas and EBV-positive T/NK-cell lymphoproliferative diseases: emerging concepts, recent advances, and the putative role of clonal hematopoiesis. A report of the 2022 EA4HP/SH lymphoma workshop.Virchows Archiv : an international journal of pathology · 2023Article
- Challenges in nodal peripheral T-cell lymphomas: from biological advances to clinical applicability.Frontiers in oncology · 2023Review
- The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.Leukemia · 2022Review
- Classification and challenges in the histopathological diagnosis of peripheral T-cell lymphomas, emphasis on the WHO-HAEM5 updates.Frontiers in oncology · 2022Review
- Clinicopathologic Features of Peripheral T-Cell Lymphoma in Sub-Saharan Africa.American journal of clinical pathology · 2021Article
- Nodal EBV+ cytotoxic T-cell lymphoma: A literature review based on the 2017 WHO classification.Journal of clinical and experimental hematopathology : JCEH · 2020Review
- MicroRNA-150 enhances radiosensitivity by inhibiting the AKT pathway in NK/T cell lymphoma.Journal of experimental & clinical cancer research : CR · 2018Article
- Extranodal NK/T Cell Lymphoma, Nasal Type (ENKTL-NT): An Update on Epidemiology, Clinical Presentation, and Natural History in North American and European Cases.Current hematologic malignancy reports · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The classification of mature NK-/T-cell lymphoma mainly originating from the T-cell lineage with predominantly nodal involvement and Epstein-Barr virus (EBV) positivity in a majority of tumor cells is unresolved. We analyzed the clinical features and treatment outcomes of such patients. Five patients with EBV-positive nodal T-cell lymphoma were surveyed during follow-up period. The median age was 53 years (range 33-88 years), and all patients showed nodal involvement. The patients mostly presented advanced clinical features, such as stage III or IV disease, elevated lactate dehydrogenase, and hemophagocytosis. Four patients received cyclophosphamide-containing chemotherapy at the time of diagnosis. However, three patients (75 %) showed disease progression during the early cycles of initial treatment. The median overall survival was 1.5 months (95 % CI 0.0-3.4 months). Patients with EBV-positive nodal T-cell lymphoma mainly show lymph node involvement, but also show aggressive clinical features and poor treatment outcomes, such as aggressive NK-cell leukemia. Therefore, we should consider EBV-positive nodal T-cell lymphoma to be a unique disease entity distinct from peripheral T-cell lymphoma not otherwise specified.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.